Completed PHASE3 INTERVENTIONAL NCT00309725

A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study.

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Interventions galantamine

Updated 5 times since 2017 Last updated: May 17, 2011 Completion: Oct 31, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00309725, this PHASE3 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.